BNTX BioNTech SE ADRs

BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders. The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$109.21  -3.13 (-2.78%)
As of 02/26/2021 15:59:55 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
ADRs
Large cap
Health Care
Biotechnology
Germany

10/10/2019
240,785,575
1,799,853
$26,252,851,242
0.00%
SEC Edgar Online
20-F
09075V102
US09075V1026
BK6H543

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
28.30
161.39
-44.19%
-252.01%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy